Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Rethink weight limits on morning-after pill

Lauren Vogel
CMAJ July 14, 2015 187 (10) 719-720; DOI: https://doi.org/10.1503/cmaj.109-5098
Lauren Vogel
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

I’m no stranger to the late-night emergency contraceptive run. I’m married, accidents happen, and I don’t want to take any chances. But the last time I tried to buy Plan B — one of four levonorgestrel “morning-after” pills sold in Canada — the pharmacist at my local drugstore turned me away.

I can’t sell you this, she said. Have you heard about the weight limit? Health Canada says this won’t work if you weigh more than 165 pounds. (That’s not exactly what the regulator says, but more on that later.)

I hadn’t heard about a limit, or told her my weight for that matter. Given that Health Canada has rated levonorgestrel as a Schedule III drug, I should be able to purchase it off the shelf without consulting a pharmacist. I asked the pharmacist about the strength of evidence for the recommendation, or if my body mass index (BMI) mattered, and since she didn’t know, I asked to buy the pill anyway. She told me to see a doctor and asked to serve the next customer. I bought the pill from the drugstore down the road, where the pharmacist didn’t mention a weight limit.

Both interactions were troubling — either the first pharmacist was misinformed or the second had sold me a drug that wouldn’t work. As it turned out, such situations are not uncommon. Dr. Edith Guilbert, a senior medical advisor for the Institut national de santé publique du Québec, has heard similar reports of Quebec pharmacists refusing to sell levonorgestrel to heavier women. She says these incidents are unjustified given the lack of consensus on the impact of body weight on the drug’s efficacy.

“It might be less effective for women who weigh more than 165 pounds or have a BMI over 25, but to say there will be no efficacy is wrong, because we have no baseline statistics on the risk of pregnancy in women who are consulting for emergency contraception,” explains Guilbert, who is co-chair of the Canadian Consensus on Contraception at the Society Obstetricians and Gynaecologists of Canada.

Figure

Health Canada recommendations on emergency contraception and body weight unduly limit “morning-after” options for many women, say experts.

Image courtesy of MOF/iStock

Health Canada is the only regulator that currently recommends overweight and obese women seek alternative methods of emergency contraception, stating that levonorgestrel may be less effective in women over 165 pounds and ineffective in women over 176 pounds. This potentially represents more than half of all Canadian women over 18. The warning, issued in March 2014, is based on a 2011 meta-analysis that showed that obese women taking the drug had a fourfold greater risk of pregnancy than women of normal weight.

However, a European Medicines Agency review later in 2014 determined that the “data available are too limited and not robust enough to conclude with certainty that contraceptive effect is reduced with increased bodyweight.” The agency advised women to continue using levonorgestrel regardless of their weight, ideally “as soon as possible” after unprotected sex in order to increase the likelihood that the drug will work.

The Society of Obstetricians and Gynaecologists of Canada has taken a similar stance, recommending that, until better evidence is available, women with a BMI over 30 “should not be discouraged” from using levonorgestrel if they can’t access or don’t want a copper intrauterine device (IUD) — the only alternative emergency contraceptive available in Canada.

This stance is also endorsed by the Canadian Pharmacists Association, according to Director of Pharmacy Innovation Phil Emberley. He says reports of women being denied levonorgestrel are concerning, and likely a product of “murky” guidelines on the issue. “We don’t know the degree to which efficacy drops off based on weight; we don’t have hard and fast milestones to go by.”

Emberley also notes that it’s rare for a single study to merit a sea change in practice. “Usually it’s a body of evidence over time that moves clinical decision-making in a certain direction.”

At the same time, “pharmacists are responsible for the medication they sell in their dispensaries and part of that responsibility is educating the public on how to use those drugs appropriately.” Such counselling should ideally happen in private, he adds. And in the case of “off the shelf” drugs, any final decision should rest with the customer.

More evidence is needed to justify a refusal, particularly given the short time women have to access other forms of contraception, says Emberley.

Right now, a woman turned away from her pharmacist has only one option for emergency contraception: getting a copper IUD inserted into her uterus by a physician. Copper IUDs are more than 99% effective at preventing pregnancy, but they can be expensive (up to several hundred dollars) and finding a doctor to insert the device within the recommended 120 hours can be difficult. One American study shows 85% of clinicians never recommend the device for emergency contraception, and 93% required two or more visits for an insertion.

The intimate nature of insertion, and the fact that IUDs can cause heavier, longer and more painful periods, also means the device isn’t appropriate for everyone, says Guilbert.

A new emergency contraceptive drug, ulipristal acetate, will become available in Canada under the brand name Ella in the fall this year. The drug is currently available as an emergency contraceptive in Europe and the United States. There’s evidence it’s also more effective than levonorgestrel for women with a BMI over 30, says Guilbert. “The risk of unintended pregnancy is much less, like 2.5%, compared to almost 6% for women using levonorgestrel.”

However, the introduction of Ella won’t dramatically improve access to emergency contraception for heavier women, as the drug will only be available by prescription. “It could take one or two years before it can become over the counter,” explains Guilbert. In the meantime, “Health Canada should withdraw their recommendations regarding weight and levonorgestrel.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 187 (10)
CMAJ
Vol. 187, Issue 10
14 Jul 2015
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Rethink weight limits on morning-after pill
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rethink weight limits on morning-after pill
Lauren Vogel
CMAJ Jul 2015, 187 (10) 719-720; DOI: 10.1503/cmaj.109-5098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Rethink weight limits on morning-after pill
Lauren Vogel
CMAJ Jul 2015, 187 (10) 719-720; DOI: 10.1503/cmaj.109-5098
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Longer family medicine residency: Boon or bane to doctor supply?
  • The evolving picture of long COVID
  • When are shared decisions false choices?
Show more News

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drugs: urogenital
    • Reproductive health, infertility & pregnancy

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire